Quantcast
Last updated on April 19, 2014 at 1:20 EDT

Latest Pseudomonas Stories

2009-12-22 07:00:00

WOBURN, Mass. and VEDBAEK, Denmark, Dec. 22 /PRNewswire/ -- AdvanDx today announced that it has received FDA 510(k) clearance for a fast, 90 minutes protocol for its E. coli/P. aeruginosa PNA FISH® and EK/P. aeruginosa PNA FISH® tests. The faster protocol reduces the PNA FISH turn-around time from the original 2.5 hours to 90 minutes by reducing PNA probe hybridization from 90 minutes to 30 minutes. Clinical validation studies performed at hospitals...

2009-12-19 00:36:54

Researchers at Binghamton University, State University of New York, have identified three key regulators required for the formation and development of biofilms. The discovery could lead to new ways of treating chronic infections. Biofilms "” communities of bacteria in self-produced slime "” may be found almost anywhere that solids and liquids meet, whether in nature, in hospitals or in industrial settings. Biofilms are implicated in more than 80 percent of chronic inflammatory and...

2009-12-14 07:30:00

SAN DIEGO, Dec. 14 /PRNewswire/ -- Pfenex Inc. announced today that it has granted Merck & Co., Inc., through an affiliate, an exclusive worldwide license to Pfenex Expression Technology(TM) Pseudomonas-based recombinant protein expression technology for the production of specific proteins to be used in the development of an undisclosed vaccine candidate. Under the terms of the agreement Pfenex is eligible to receive approximately $52 million in upfront and milestone payments as well...

2009-12-02 18:00:00

NEW YORK, Dec. 2 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Antibiotic Resistance and Antibiotic Technologies: Global Markets http://www.reportlinker.com/p0166825/Antibiotic-Resistance-and-Antibiotic-Technologies-Global-Markets.html Provide an in-depth review of the global market for antibiotics resistance and antibiotics technologies Offer an analysis of antibiotics resistance from an historical vantage point Measure...

399247cf51ca4ad36a5968b8bf07eb4d
2009-11-05 07:55:18

Scientists observe the emergence of a new adaptation strategy to rapidly changing environmental conditions Organisms ensure the survival of their species by genetically adapting to the environment. If environmental conditions change too rapidly, the extinction of a species may be the consequence. A strategy to successfully cope with such a challenge is the generation of variable offspring that can survive in different environments. Even though a portion of the offspring may have a decreased...

e024789dd117710d9c2e1e213120f81a
2009-11-02 06:53:43

Researchers from the University of Copenhagen and the Technical University of Denmark along with other collaborators in Denmark and the US found that the bacterium Pseudomonas aeruginosa can 'switch on' production of molecules that kill white blood cells "“ preventing the bacteria being eliminated by the body's immune system. P. aeruginosa is responsible for many hospital-acquired infections and also causes chronic infections in those with pre-existing medical conditions such as cystic...

2009-10-19 08:00:00

MONMOUTH JUNCTION, N.J., Oct. 19 /PRNewswire/ -- Transave Inc., today reported additional positive clinical trial results on its lead investigational drug, ARIKACE(TM) (liposomal amikacin for inhalation), an antibiotic that aims to treat chronic lung infections. The latest results along with previously reported data demonstrate significant clinical benefits and complete the company's Phase II program in two indications - for the treatment of lung infections due to the bacterium,...

2009-09-14 10:02:40

Arbonne International of Irvine, Calif., is recalling one lot of its Seasource Detox Spa-brand foaming sea salt scrub due to possible bacterial contamination. The company said the recalled product was manufactured by a third party and distributed nationwide through Arbonne. The recalled scrub is sold in a 6.8-ounce white tube and is identified with the lot number Z928 printed on the crimping at the top of the tube. The U.S. Food and Drug Administration said the voluntary recall was initiated...

2009-09-14 07:00:00

MONMOUTH JUNCTION, N.J., Sept. 14 /PRNewswire/ -- Transave, Inc., today reported positive results from a Phase II clinical trial in non-cystic fibrosis (CF) bronchiectasis patients for its lead investigational drug, ARIKACE(TM) (liposomal amikacin for inhalation). The Phase II data indicated that ARIKACE, delivered once daily for 28 consecutive days, demonstrated superior clinical benefit compared to placebo as measured by patient and physician reported outcomes and reduction in Pseudomonas...

2009-09-11 18:50:00

SAN DIEGO, Sept. 11 /PRNewswire/ -- Calixa Therapeutics Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of novel antibiotics for the treatment of antibiotic-resistant infections, will present pre-clinical and clinical data in 20 posters at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) that is being held in San Francisco on September 12 to 15, 2009. The presentations will include comprehensive in vitro, in vivo,...


Latest Pseudomonas Reference Libraries

0_85d9abd5d0844260722ff2e72fcc9f5a
2011-04-25 21:18:54

Pseudomonas aeruginosa is a common bacterium that can cause disease in animals and humans. It can be found in soil, water, skin flora, and most man-made environments throughout the world. It thrives in normal or hypoxic atmospheres; due to this it has colonized many natural and artificial environments. It can infect animals with damaged tissue or people with reduced immunity. Symptoms are generalized inflammation and sepsis. It can be fatal if colonization occurs in critical body organs,...

More Articles (1 articles) »